Conditioned Placebo Dose Reduction: A New Treatment in Attention-Deficit Hyperactivity Disorder?
- 1 June 2010
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Developmental & Behavioral Pediatrics
- Vol. 31 (5), 369-375
- https://doi.org/10.1097/dbp.0b013e3181e121ed
Abstract
Objective: This study examined if pairing a placebo with stimulant medication produces a placebo response that allows children with attention-deficit hyperactivity disorder (ADHD) to be maintained on a lower dose of stimulant medication. The primary aim was to determine the efficacy, side effects, and acceptability of a novel conditioned placebo dose reduction procedure. Method: Participants included 99 children ages 6 to 12 years with ADHD. After an initial double-blind dose finding to identify optimal dose of mixed amphetamine salts, subjects were randomly assigned to 1 of 3 treatments of 8-week duration: (a) conditioned placebo dose reduction condition (50% reduced dose/placebo [RD/P]) or (b) a dose reduction only condition (RD) or (c) a no reduction condition (full dose). The innovative conditioned placebo dose reduction procedure involved daily pairing of mixed amphetamine salts dose with a visually distinctive placebo capsule administered in open label, with full disclosure of placebo use to subjects and parents. Results: Seventy children completed the study. There were no differences in subject retention among the 3 groups. Most subjects in the RD/P group remained stable during the treatment phase, whereas most in the RD group deteriorated. There was no difference in control of ADHD symptoms between the RD/P group and the full dose group, and both RD/P and full dose groups showed better ADHD control than the RD group. Treatment emergent side effects were lowest in the RD/P group. Conclusion: Pairing placebos with stimulant medication elicits a placebo response that allows children with ADHD to be effectively treated on 50% of their optimal stimulant dose.Keywords
This publication has 36 references indexed in Scilit:
- Are There Placebo Effects in the Medication Treatment of Children With Attention-Deficit Hyperactivity Disorder?Journal of Developmental & Behavioral Pediatrics, 2009
- Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Open‐label use of placebos in the treatment of ADHD: a pilot studyChild: Care, Health and Development, 2007
- Children's and parents' perspectives on open‐label use of placebos in the treatment of ADHDChild: Care, Health and Development, 2007
- Placebo effects in developmental disabilities: Implications for research and practiceMental Retardation and Developmental Disabilities Research Reviews, 2005
- The Functional Neuroanatomy of the Placebo EffectAmerican Journal of Psychiatry, 2002
- Effects of methyphenidate and expectancy on children with ADHD: Behavior, academic performance, and attributions in a summer treatment program and regular classroom settings.Journal of Consulting and Clinical Psychology, 2002
- Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity DisorderPEDIATRICS, 2001
- Placebo Effects in AutismJournal of Developmental & Behavioral Pediatrics, 2000
- Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity DisorderPEDIATRICS, 2000